Opioid Withdrawal Syndrome (OWS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Opioid Withdrawal Syndrome (OWS) Market Outlook
Thelansis’s “Opioid Withdrawal
Syndrome (OWS) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Opioid Withdrawal Syndrome (OWS)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Opioid
Withdrawal Syndrome (OWS) Overview
Opioid
withdrawal syndrome is a life-threatening situation that arises from dependence
on opioids, a class of medications employed to alleviate intense pain. This
syndrome manifests when individuals reliant on opioids abruptly decrease or
cease their intake. The locus coeruleus, situated at the brain’s base, serves
as the primary trigger for the onset of opioid withdrawal syndrome. Within this
region, neurons are noradrenergic and feature an elevated density of opioid
receptors. Following opioid use, urine toxicology typically detects opioids
such as morphine, heroin, codeine, oxycodone, and propoxyphene for a period
spanning 12 to 36 hours. The Clinical Opioid Withdrawal Scale (COWS) is
commonly employed to determine the severity of opioid withdrawal symptoms.
Pharmacological intervention becomes necessary upon the presentation of signs
of opioid withdrawal. Methadone or buprenorphine are utilized for long-term
opioid replacement, with methadone administration occurring in both inpatient
and outpatient treatment settings.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment